Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term IRRADIATION. Found 13 abstracts

Lawton CA, Michalski J, El-Naqa I, Buyyounouski MK, Lee WR, Menard C, O'Meara E, Rosenthal SA, Ritter M, Seider M. RTOG GU RADIATION ONCOLOGY SPECIALISTS REACH CONSENSUS ON PELVIC LYMPH NODE VOLUMES FOR HIGH-RISK PROSTATE CANCER. International Journal of Radiation Oncology Biology Physics. 2009 Jun;74(2):383-7.   PMCID: PMC2905150
Small W, Mell LK, Anderson P, Creutzberg C, De Los Santos J, Gaffney D, Jhingran A, Portelance L, Schefter T, Iyer R, Varia M, Winter K, Mundt AJ. Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy in postoperative treatment of endometrial and cervical cancer. International Journal of Radiation Oncology Biology Physics. 2008 Jun;71(2):428-34.
Trabulsi EJ, Valicenti RK, Hanlon AL, Pisansky TM, Sandler HM, Kuban DA, Catton CN, Michalski JM, Zelefsky MJ, Kupelian PA, Lin DW, Anscher MS, Slawin KM, Roehrborn CG, Forman JD, Liauw SL, Kestin LL, DeWeese TL, Scardino PT, Stephenson AJ, Pollack A. A Multi-Institutional Matched-Control Analysis of Adjuvant and Salvage Postoperative Radiation Therapy for pT3-4N0 Prostate Cancer. Urology. 2008 Dec;72(6):1298-302.
Chang DT, Feigenberg SJ, Indelicato DJ, Morris CG, Lightsey J, Grobmyer SR, Copeland EM, Mendenhall NP. Long-term outcomes in breast cancer patients with ten or more positive axillary nodes treated with combined-modality therapy: The importance of radiation field selection. International Journal of Radiation Oncology Biology Physics. 2007 Mar;67(4):1043-51.
Fan J, Luo W, Fourkal E, Lin T, Li J, Veltchev I, Ma CM. Shielding design for a laser-accelerated proton therapy system. Physics in Medicine and Biology. 2007 Jul;52(13):3913-30.
Fizazi K, Le Maitre A, Hudes G, Berry WR, Kelly WK, Eymord JC, Logothetis CJ, Pignon JP, Michiels S. Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data. Lancet Oncology. 2007 Nov;8(11):994-1000.
Zelefsky MJ, Kuban DA, Levy LB, Potters L, Beyer DC, Blasko JC, Moran BJ, Ciezki JP, Zietman AL, Pisansky TM, Elshaikh M, Horwitz EM. Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation. International Journal of Radiation Oncology Biology Physics. 2007 Feb;67(2):327-33.
Lilenbaum RC, Huber RM, Treat J, Masters G, Kaubitzsch S, Lane S, Wissel P. Topotecan therapy in patients with relapsed small-cell lung cancer and poor performance status. Clinical lung cancer. 2006 Sep;8(2):130-4.
Ray ME, Levy LB, Horwitz EM, Kupelian PA, Martinez AA, Michalski JM, Pisansky TM, Zelefsky MJ, Zietman AL, Kuban DA. Nadir prostate-specific antigen within 12 months after radiotherapy predicts biochemical and distant failure. Urology. 2006 Dec;68(6):1257-62.
Andrews SF, Anderson PR, Eisenberg BL, Hanlon AL, Pollack A. Soft tissue sarcomas treated with postoperative external beam radiotherapy with and without low-dose-rate brachytherapy. International Journal of Radiation Oncology Biology Physics. 2004 Jun;59(2):475-80.
Jacob R, Hanlon AL, Horwitz EM, Movsas B, Uzzo RG, Pollack A. The relationship of increasing radiotherapy dose to reduced distant metastases and mortality in men with prostate cancer. Cancer. 2004 Feb;100(3):538-43.
Treat J, Huang CH, Lane SR, Levin J. Topotecan in the treatment of relapsed small cell lung cancer patients with poor performance status. The oncologist. 2004 Jan;9(2):173-81.
Kuban DA, Thames HD, Levy LB, Horwitz EM, Kupelian PA, Martinez AA, Michalski JM, Pisansky TM, Sandler HM, Shipley WU, Zelefsky MJ, Zietman AL. Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with radiotherapy in the PSA era. Int J Radiat Oncol Biol Phys. 2003 Nov 15;57(4):915-28.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term IRRADIATION

IRRADIATION radiotherapy KeyWords Plus: CARCINOMA RADICAL PROSTATECTOMY THERAPY TRIAL CHEMOTHERAPY RADIATION-THERAPY CYCLOPHOSPHAMIDE prostate cancer palliative care ADENOCARCINOMA VINCRISTINE BIOCHEMICAL FAILURE brachytherapy PROGNOSTIC FACTORS ETOPOSIDE lung neoplasms mortality ADJUVANT BRACHYTHERAPY RANDOMIZED PHASE-III ACUTE HEMATOLOGIC TOXICITY POSTMASTECTOMY RADIOTHERAPY dose CONFORMAL RADIOTHERAPY BIOCHEMICAL CONTROL EXTENDED-FIELD COMBINATION PATIENT SELECTION RESECTION HIGH-DOSE CHEMOTHERAPY FEASIBILITY SURGICAL ADJUVANT BREAST CARCINOMA-CELLS prostate-specific antigen IMRT PLASMA INTERACTIONS pelvic GENERATION DEPRIVATION REGIMENS FOLLOW-UP EFFICACY PHOSPHATE I-125 GROUP CONSERVING THERAPY RADICAL MULTIINSTITUTIONAL ANALYSIS BRACHYTHERAPY Radiation FAILURE NEUTRON DOSE-EQUIVALENT adjuvant therapy ANTIGEN LEVEL adverse effects AGE EXTREMITY prostate carcinoma BEAM RADIATION-THERAPY IMPACT BONY LANDMARKS Target volume CONFORMAL RADIATION-THERAPY MALIGNANCIES NEOADJUVANT CONSERVATIVE SURGERY PHASE-III HOOSIER ONCOLOGY cervical cancer lymph nodes intensity-modulated radiotherapy DOCETAXEL EQUAL-TO 70 CURE RANDOMIZED PHASE-II local control EXTERNAL-BEAM RADIOTHERAPY LYMPHADENECTOMY DOXORUBICIN oncology guidelines Prostate cancer breast neoplasms CISPLATIN combined-modality therapy CLINICAL TARGET VOLUME endometrial cancer RADIOTHERAPY TUBULIN topotecan electrons REGIONAL NODAL PSA ERA PREMENOPAUSAL WOMEN RANDOMIZED TRIAL LYMPH-NODES DEFINITION AUTOLOGOUS BONE-MARROW PATTERNS PROSTATECTOMY multi-institutional analysis ANDROGEN SUPPRESSION SURVIVAL ADVANTAGE isotope metastasis antitumor activity ADJUVANT TREATMENT CANCER Pelvic lymph nodes PSA NADIR adjuvant DISEASE-FREE SURVIVAL HIGH-INTENSITY LASER sarcoma HIGH-RISK pooled analysis salvage therapy RADIATION AMERICAN SOCIETY OUTCOMES long-term outcome BEAMS MITOXANTRONE PLUS PREDNISONE GYNECOLOGIC ION-ACCELERATION EXPOSURES EXTERNAL-BEAM RADIATION dose escalation MARROW
Last updated on Sunday, July 05, 2020